Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

351 - Evaluation of palonosetron in combination with 1-day dexamethasone for chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of paclitaxel and carboplatin for gynecologic malignancies


20 Dec 2015


Poster presentation 2


naoto Furukawa


Annals of Oncology (2015) 26 (suppl_9): 111-124. 10.1093/annonc/mdv531


N. Furukawa1, F. Ito2, N. Kawahara1, S. Komeda1

Author affiliations

  • 1 Obstetrics And Gynecology, Nara Prefecture Western Medical Center, 636-0802 - Nara/JP
  • 2 Obstetrics And Gynecology, Nara Medical University, 634-8522 - Nara/JP


Abstract 351


Palonosetron (PAL) may prevent chemotherapy-induced nausea and vomiting (CINV) for paclitaxel and carboplatin (TC) in the delayed phase without dexamethasone (DEX) on days 2 and 3. This retrospective study was designed to compare PAL plus DEX on day 1 only (D-1 group) with PAL plus DEX on days 1-3 (D-3 group) with respect to complete response (CR) rate for delayed CINV in patients receiving multiple cycles of TC.


There were 89 patients receiving TC in our institution between 2011 and 2013. Of these 89, 61 receiving four cycles of TC were included and evaluated using the Multinational Association of Supportive Care in Cancer Antiemesis Tool. A chi-square test was used to compare the CR rates between groups. Logistic regression analysis was used to evaluate univariate and multivariate associations with clinical parameters on CR rate.


The patients was 29 for the D-3 group and 32 for the D-1 group. There was no significant difference in the CR rates in cycles 1-4 between groups. There was also no significant difference in the complete control rates and the total control rates in each cycle between groups. Multivariate analysis performed with CR rate as an endpoint revealed that the only independent predictor was age under 50 years in cycle 3 and 4 (p = 0.043 and 0.005, respectively).


Combined treatment with PAL and DEX was effective for preventing delayed CINV in patients receiving TC, but age under 50 years was the risk factor for delayed CINV when cycle of chemotherapy increased.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings